{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:46:38Z","timestamp":1791913598652,"version":"4.3.4"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.lungcan.2021.10.020","type":"journal-article","created":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T11:38:56Z","timestamp":1636198736000},"page":"154-161","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":77,"special_numbering":"C","title":["Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations"],"prefix":"10.1016","volume":"162","author":[{"given":"Lyudmila","family":"Bazhenova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Minchom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Viteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua M.","family":"Bauml","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai-Hong Ignatius","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirish M.","family":"Gadgeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Manuel","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Backenroth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Londhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parthiv","family":"Mahadevia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.lungcan.2021.10.020_b0005","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.lungcan.2021.10.020_b0010","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2021.10.020_b0015","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.lungcan.2021.10.020_b0020","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2021.10.020_b0025","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","article-title":"Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial","volume":"15","author":"Wu","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2021.10.020_b0030","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(14)71173-8","article-title":"Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2021.10.020_b0035","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1158\/1535-7163.MCT-12-0620","article-title":"EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics","volume":"12","author":"Arcila","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"10","key":"10.1016\/j.lungcan.2021.10.020_b0040","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jtho.2018.06.019","article-title":"Diverse EGFR exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC","volume":"13","author":"Riess","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.lungcan.2021.10.020_b0045","doi-asserted-by":"crossref","first-page":"302","DOI":"10.21037\/tlcr.2019.04.12","article-title":"Treatment of uncommon EGFR mutations in non-small cell lung cancer: new evidence and treatment","volume":"8","author":"Zhang","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"10","key":"10.1016\/j.lungcan.2021.10.020_b0050","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2011.36.8456","article-title":"First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung","volume":"30","author":"Han","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.lungcan.2021.10.020_b0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/annonc\/mds214","article-title":"North-East Japan Study, Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.lungcan.2021.10.020_b0060","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","article-title":"West Japan Oncology, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial","volume":"11","author":"Mitsudomi","year":"2010","journal-title":"Lancet Oncol"},{"issue":"25","key":"10.1016\/j.lungcan.2021.10.020_b0065","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1056\/NEJMoa0909530","article-title":"North-East Japan Study, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lungcan.2021.10.020_b0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall survival with osimertinib in untreated","volume":"382","author":"Ramalingam","year":"2020","journal-title":"EGFR-mutated advanced NSCLC, N Engl J Med"},{"issue":"2","key":"10.1016\/j.lungcan.2021.10.020_b0075","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N Engl J Med"},{"issue":"7878","key":"10.1016\/j.lungcan.2021.10.020_b0080","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/s41586-021-03898-1","article-title":"Structure-based classification predicts drug response in EGFR-mutant NSCLC","volume":"597","author":"Robichaux","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.lungcan.2021.10.020_b0085","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41392-019-0038-9","article-title":"Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer","volume":"4","author":"Vyse","year":"2019","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"10.1016\/j.lungcan.2021.10.020_b0090","doi-asserted-by":"crossref","first-page":"e620","DOI":"10.1016\/j.cllc.2019.06.018","article-title":"Effectiveness of treatments for advanced non-small-cell lung cancer with exon 20 insertion epidermal growth factor receptor mutations","volume":"20","author":"Wu","year":"2019","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.lungcan.2021.10.020_b0095","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S1470-2045(15)00026-1","article-title":"Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6","volume":"16","author":"Yang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.lungcan.2021.10.020_b0100","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.2147\/OTT.S108242","article-title":"Clinical efficacy of first-generation EGFR-TKIs in patients with advanced non-small-cell lung cancer harboring EGFR exon 20 mutations","volume":"9","author":"Chen","year":"2016","journal-title":"Onco Targets Ther"},{"issue":"15","key":"10.1016\/j.lungcan.2021.10.020_b0105","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.2217\/fon-2017-0666","article-title":"Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies","volume":"14","author":"Cappuzzo","year":"2018","journal-title":"Future Oncol"},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2021.10.020_b0110","doi-asserted-by":"crossref","first-page":"9580","DOI":"10.1200\/JCO.2020.38.15_suppl.9580","article-title":"Indirect comparison of TAK-788 vs real-world data outcomes in refractory non-small cell lung cancer (NSCLC) with EGFR exon 20 insertions","volume":"38","author":"Horn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2021.10.020_b0115","doi-asserted-by":"crossref","first-page":"9514","DOI":"10.1200\/JCO.2020.38.15_suppl.9514","article-title":"Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients [poster]","volume":"38","author":"Le","year":"2020","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.lungcan.2021.10.020_b0120","doi-asserted-by":"crossref","first-page":"9077","DOI":"10.1200\/JCO.2021.39.15_suppl.9077","article-title":"Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20)","volume":"39","author":"Piotrowska","year":"2021","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1016\/j.lungcan.2021.10.020_b0125","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1186\/s12885-019-5820-0","article-title":"EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer","volume":"19","author":"Fang","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2021.10.020_b0130","doi-asserted-by":"crossref","unstructured":"B. van Veggel, R.S.J.F.V. Madeira, S.M.S. Hashemi, M.S. Paats, K. Monkhorst, D.A.M. Heideman, M. Groves, T. Radonic, E.F. Smit, E. Schuuring, A.J. van der Wekken, A.J. de Langen, Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer, Lung Cancer (Amsterdam, Netherlands) 141 (2020) 9-13.","DOI":"10.1016\/j.lungcan.2019.12.013"},{"key":"10.1016\/j.lungcan.2021.10.020_b0135","unstructured":"RYBREVANT\u00ae (amivantamab-vmjw) injection, for intravenous use [Prescribing Information]. Janssen Pharmaceutical Companies, Horsham, PA, 2021."},{"issue":"30","key":"10.1016\/j.lungcan.2021.10.020_b0140","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1200\/JCO.21.00662","article-title":"Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study","volume":"39","author":"Park","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.lungcan.2021.10.020_b0145","unstructured":"EXKIVITYTM (mobocertinib) capsules, for oral use [Prescribing Information]. Takeda Pharmaceuticals America, Inc. Lexington, MA, (2021)."},{"issue":"10","key":"10.1016\/j.lungcan.2021.10.020_b0150","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1158\/1078-0432.CCR-20-4650","article-title":"Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions","volume":"27","author":"Choudhury","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.lungcan.2021.10.020_b0155","doi-asserted-by":"crossref","first-page":"S681","DOI":"10.1016\/j.jtho.2019.08.1446","article-title":"P2.01-103 Real-World Treatment Patterns and Survival in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations","volume":"14","author":"Dersarkissian","year":"2019","journal-title":"Journal of Thoracic Oncology"},{"issue":"S3","key":"10.1016\/j.lungcan.2021.10.020_b0160","first-page":"S247","article-title":"Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer, Transl Lung","volume":"8","author":"Andrews Wright","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.lungcan.2021.10.020_b0165","unstructured":"U.S. Food and Drug Administration. FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations, 2018. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations. Accessed January 15, 2021."},{"issue":"18","key":"10.1016\/j.lungcan.2021.10.020_b0170","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1002\/cncr.29493","article-title":"Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib","volume":"121","author":"Naidoo","year":"2015","journal-title":"Cancer"},{"issue":"216","key":"10.1016\/j.lungcan.2021.10.020_b0175","doi-asserted-by":"crossref","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci Transl Med"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005912?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500221005912?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:58:32Z","timestamp":1791910712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500221005912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":35,"alternative-id":["S0169500221005912"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.10.020","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative clinical outcomes for patients with advanced NSCLC harboring EGFR exon 20 insertion mutations and common EGFR mutations","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2021.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}